喀什治勃起不硬看哪个科(喀什阴茎不充血) (今日更新中)

LOS ANGELES, March 16 (Xinhua) -- The death rate in the United States reached an all-time low in 2009, dropping 2.3 percent from 2008, a newly released report said.This was the 10th straight year of decline, demonstrating that Americans are living longer than ever, according to the report from the U.S. Centers for Disease Control and Prevention's National Center for Health Statistics.The nation saw a drop from 758.7 deaths per 100,000 people in 2008 to 741 per 100,000 people in 2009 when 2,436,682 deaths were reported, said the report published by HealthDay News on Wednesday.However, life expectancy for blacks remained unchanged -- 70.9 years for men and 77.4 years for women. The disparity between whites and blacks is now 4.3 years, representing a 0.2 percent increase from 2008 to 2009, the report found.The report said that deaths fell in 10 of the 15 leading causes of death -- heart disease dropped 3.7 percent, cancer fell 1.1 percent, and stroke declined 4.2 percent.Deaths from Alzheimer's disease, diabetes, chronic lower respiratory diseases and accidents all declined 4.1 percent, according to the report.Deaths from flu and pneumonia fell 4.7 percent, and deaths from septicemia, a bacterial infection, decreased 1.8 percent, the report said.Deaths from homicides fell 6.8 percent, but suicides increased from 35,933 in 2008 to 36,547 in 2009. Other than suicide, which overtook septicemia as the 10th leading cause of death, the ranking of the leading causes of death was unchanged from 2008 to 2009, the report noted.Infant mortality hit a record low in 2009, falling from 6.59 deaths per 1,000 births in 2008 to 6.42, representing a 2.6 percent decrease, according to the report.The report, however, did not give reasons for these trends.Experts think behavioral changes, particularly the decline in smoking, are partly responsible for the improvements.The report's lead author Kenneth Kochanek, a statistician at the center, said this is preliminary data, and the final data, which should be available this summer, may shed some light on the findings.

WASHINGTON, April 3 (Xinhua) -- Scientists have confirmed that metabolic syndrome, a constellation of conditions that increases the risk of heart disease and diabetes, may also increase the risk of the two most common types of liver cancer, according to data presented at the American Association for Cancer Research's 102nd Annual Meeting 2011, held in Orlando, Florida on April 2-6.Katherine McGlynn, a senior investigator at the National Cancer Institute, said approximately one-third of the U.S. population has metabolic syndrome, which is defined as the co-occurrence of at least three of the following five conditions: raised blood pressure, elevated waist circumference, low HDL or "good" cholesterol, raised triglyceride levels and raised fasting plasma glucose levels.According to McGlynn, persons with these conditions may be at increased risk of developing hepatocellular carcinoma and intrahepatic cholangiocarcinoma.For the current study, researchers identified 3,649 cases of hepatocellular carcinoma and 743 cases of intrahepatic cholangiocarcinoma. They compared the medical history of these patients with the medical histories of 195,953 cancer-free adults.Statistical analyses showed that the persons with liver cancer were significantly more likely than cancer-free persons to have a prior history of metabolic syndrome: 37.1 percent of patients with hepatocellular carcinoma had pre-existing metabolic syndrome, as did 29.7 percent of patients with intrahepatic carcinoma; only 17.1 percent of the cancer-free adults had metabolic syndrome.Liver cancer incidence has been rising since the 1980s in the United States. The factors related to the increase are not well understood. "A lot of attention has focused on viral risk factors, but a significant part of the increase may be due to metabolic syndrome, as well as to diabetes and obesity," said McGlynn."The prognosis for liver cancer is only marginally better than the prognosis for pancreatic cancer, with a five-year survival of approximately 10 percent," she said. "Prognosis is more favorable, however, when liver cancers are diagnosed at early stages when they are small and localized to the liver."

GENEVA, May 17 (Xinhua) -- Health Ministers from Brazil, Russia, India, China and South Africa met here on Tuesday, to prepare for the BRICS Health Ministerial Meeting which is to be held in Beijing on July 11, 2011.The preparatory discussion was convened on the sidelines of the 64th World Health Assembly, which have gathered health authorities from 193 member states of the World Health Organization (WHO).In a press communique following the discussions, the Health Ministers of the BRICS said that the theme of the Beijing meeting would include, promoting innovation and access to affordable medical products, vaccines and other health technologies, in support of reaching the Millennium Development Goals and addressing other public health challenges.Additional agreement decided that the World Conference on Social Determinants of Health will be held in the Brazilian Capital, Rio de Janeiro, next October, as an important opportunity to discuss the inter-linkages between public health and development, as well as exchange experiences in reducing health inequities within and amongst countries.

ACCRA, Feb. 12 (Xinhua) -- China would in the coming years inject more capital to support the infrastructure needs of Ghana, Chinese Ambassador to Ghana Gong Jianzhong has said.Briefing the media here on Friday night to announce the visit to Ghana by Chen Deming, the Chinese Minister of Commerce, Ambassador Gong said that China is willing to join in the infrastructure development of Ghana."We are willing to join Ghana in improving its infrastructure base. We will be happy to give our contribution towards the infrastructure development of Ghana," he said.The forthcoming two-day visit by the Chinese minister would afford the two countries to further cement, promote and syncretize the bilateral trade and economic corporation existing between them for more than five decades.The ambassador said the Chinese Embassy in Ghana is committed to offering quality service to Ghanaians engaging in bilateral exchanges and cooperation in different fields.Currently, China has supported the West African country in the construction of various roads, rails, school blocks, hospitals, among others.He called on the Chinese firms in Ghana to raise investments and take corporate social responsibilities in local communities where they are operating.

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.

来源：资阳报